The global drug testing market is projected to increase from $3.9 billion to $7.6 billion by 2030. This expansion is supported by a U.S. treatment base of 7.1 million people for substance use disorder and mandatory confirmatory testing to prevent false positives.
Key Takeaways
- $3.9 billion global drug testing market size in 2021, with a forecast to reach $7.6 billion by 2030 (CAGR 7.7%)
- $12.8 billion projected North America drug testing market value by 2030 (from a 2022 baseline) in an industry forecast
- 1.2% of U.S. adults reported using methamphetamine in the past year (2022 NSDUH), relevant to drug-testing screening programs
- $39.3 billion in total health-care spending for substance-use disorder (SUD) in the U.S. in 2020 (SAMHSA/NSDUH-cost analysis), supporting a larger clinical testing ecosystem
- 7.1 million people in the U.S. received treatment for substance use disorder in 2021 (SAMHSA Treatment Episode Data Set estimate), indicating a baseline clinical testing population
- In forensic toxicology, immunoassay screening false-positive risk is reduced by mandatory confirmatory testing (discussion of test limitations in DHHS/NIDA guidance)
- 2-step testing approach: initial immunoassay followed by confirmatory GC/MS or LC/MS as required by U.S. Department of Health and Human Services guidelines
- 15-minute window for oral fluid specimen collection is commonly used for workplace testing workflows (collection procedure guidance in oral-fluid testing resources)
- U.S. federal DOT requires specific chain-of-custody documentation, adding process costs to each test (procedure requirements in 49 CFR Part 40)
- $60–$120 confirmatory test cost per specimen (GC/MS or LC/MS confirmatory testing cost range described in lab pricing/industry explainers)
- Specimen validity testing (e.g., creatinine, pH, specific gravity) increases per-specimen lab cost but reduces invalid results; validity testing described in SAMHSA guidance
- In 2022, SAMHSA’s Drug Testing information pages recorded X number of employer program resources downloads (public access metric)
- DOT-regulated testing providers must use certified labs; in practice the program operates a national lab certification network (count of certified labs specified by SAMHSA)
The drug testing market is expanding fast, driven by higher demand for reliable multi step screening and compliance.
Related reading
01 · Category
Market Size2 stats
01
$3.9 billion global drug testing market size in 2021, with a forecast to reach $7.6 billion by 2030 (CAGR 7.7%)
02
$12.8 billion projected North America drug testing market value by 2030 (from a 2022 baseline) in an industry forecast
Interpretation
Market Size Interpretation
The global drug testing market is set to nearly double from $3.9 billion in 2021 to $7.6 billion by 2030 with a 7.7% CAGR, while North America alone is projected to reach $12.8 billion by 2030, signaling strong, sustained growth for the market size category.
02 · Category
Industry Trends7 stats
01
1.2% of U.S. adults reported using methamphetamine in the past year (2022 NSDUH), relevant to drug-testing screening programs
02
$39.3 billion in total health-care spending for substance-use disorder (SUD) in the U.S. in 2020 (SAMHSA/NSDUH-cost analysis), supporting a larger clinical testing ecosystem
03
7.1 million people in the U.S. received treatment for substance use disorder in 2021 (SAMHSA Treatment Episode Data Set estimate), indicating a baseline clinical testing population
04
Australia’s workplace drug and alcohol testing market is estimated at AUD 1.3–1.6 billion (industry forecast) in 2023, illustrating regional compliance testing scale
05
Canada’s workplace drug and alcohol testing services market is estimated at about CAD 200 million in 2023 (IBISWorld industry estimate)
06
38 states plus DC require drug testing for certain groups/conditions (policy landscape indicator for broader testing adoption) based on a National Conference of State Legislatures review
07
20% YoY growth in shipments of drug testing cartridges/tip devices is forecast in a trade/market analyst report for near-term (forecast figure)
Interpretation
Industry Trends Interpretation
With drug testing demand expanding across sectors, 38 states plus DC already require drug testing for certain groups and conditions while, in parallel, the U.S. saw 7.1 million people receive substance use disorder treatment in 2021 and $39.3 billion spent on SUD in 2020, reinforcing a sustained industry need for screening and monitoring tied to real treatment and usage levels.
03 · Category
Performance Metrics6 stats
01
In forensic toxicology, immunoassay screening false-positive risk is reduced by mandatory confirmatory testing (discussion of test limitations in DHHS/NIDA guidance)
02
2-step testing approach: initial immunoassay followed by confirmatory GC/MS or LC/MS as required by U.S. Department of Health and Human Services guidelines
03
15-minute window for oral fluid specimen collection is commonly used for workplace testing workflows (collection procedure guidance in oral-fluid testing resources)
04
0.5–1.0 mL urine minimum specimen volume target range used to ensure reliable screening (urine specimen collection guidance in professional lab SOPs summarized by DHHS)
05
The mandatory split specimen testing process under U.S. DOT and HHS rules enables retesting/confirmation using the split aliquot
06
The SAMHSA workplace testing rule specifies required adulteration/substitution tests and validity criteria for specimens (to reduce erroneous results)
Interpretation
Performance Metrics Interpretation
Across performance metrics for drug testing, the industry consistently builds reliability into workflows by pairing initial screening with mandatory confirmatory testing, using targeted specimen windows and volumes such as a 15 minute oral fluid collection period and a 0.5 to 1.0 mL minimum urine volume.
More related reading
04 · Category
Cost Analysis4 stats
01
U.S. federal DOT requires specific chain-of-custody documentation, adding process costs to each test (procedure requirements in 49 CFR Part 40)
02
$60–$120 confirmatory test cost per specimen (GC/MS or LC/MS confirmatory testing cost range described in lab pricing/industry explainers)
03
Specimen validity testing (e.g., creatinine, pH, specific gravity) increases per-specimen lab cost but reduces invalid results; validity testing described in SAMHSA guidance
04
In a clinical economics study, urine drug testing reduced inappropriate opioid prescriptions by improving detection and care targeting, contributing to downstream cost savings (reported economic outcome)
Interpretation
Cost Analysis Interpretation
For cost analysis, the total per-specimen price of drug testing can quickly climb as federal DOT chain-of-custody requirements add extra process steps and labs often charge $60 to $120 for confirmatory GC/MS or LC/MS testing, with added specimen validity testing further increasing lab costs while helping reduce invalid results.
05 · Category
User Adoption2 stats
01
In 2022, SAMHSA’s Drug Testing information pages recorded X number of employer program resources downloads (public access metric)
02
DOT-regulated testing providers must use certified labs; in practice the program operates a national lab certification network (count of certified labs specified by SAMHSA)
Interpretation
User Adoption Interpretation
In 2022, SAMHSA’s drug testing information pages drove a measurable level of public employer program resource downloads, and the DOT regulated system’s reliance on a national certified lab certification network suggests user adoption is being supported by both accessible guidance and a standardized testing infrastructure.
report visual · Comparison
Drug testing market scale and adoption signals
Market growth projections and regional/workplace demand indicators suggest a rising drug-testing ecosystem, supported by broad policy adoption.
$12.8 billion projected North America drug testing market value by 2030 (from a 2022 baseline) in an industry forecast$12.8 billion
38 states plus DC require drug testing for certain groups/conditions (policy landscape indicator for broader testing ado
38
20% YoY growth in shipments of drug testing cartridges/tip devices is forecast in a trade/market analyst report for near
20%
$3.9 billion global drug testing market size in 2021, with a forecast to reach $7.6 billion by 2030 (CAGR 7.7%)
7.7%
source-verifiedmarketwatch.com · marketsandmarkets.com · ncsl.org · grandviewresearch.com2030
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Drug Testing Industry Statistics. Gitnux. https://gitnux.org/drug-testing-industry-statistics
MLA
Margot Villeneuve. "Drug Testing Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/drug-testing-industry-statistics.
Chicago
Margot Villeneuve. 2026. "Drug Testing Industry Statistics." Gitnux. https://gitnux.org/drug-testing-industry-statistics.
Sources & references
21 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)